Citigroup Inc. Boosts Stake in Catalent, Inc. (NYSE:CTLT)

Citigroup Inc. raised its position in Catalent, Inc. (NYSE:CTLT - Free Report) by 26.2% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 204,923 shares of the company's stock after purchasing an additional 42,517 shares during the period. Citigroup Inc. owned 0.11% of Catalent worth $12,412,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of CTLT. Sumitomo Mitsui Trust Group Inc. raised its position in shares of Catalent by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company's stock worth $24,550,000 after acquiring an additional 14,373 shares in the last quarter. Quest Partners LLC raised its holdings in Catalent by 289.8% during the third quarter. Quest Partners LLC now owns 49,300 shares of the company's stock worth $2,986,000 after purchasing an additional 36,652 shares in the last quarter. Swedbank AB purchased a new stake in shares of Catalent during the 1st quarter worth approximately $1,659,000. New York Life Investment Management LLC boosted its holdings in shares of Catalent by 67.9% in the 2nd quarter. New York Life Investment Management LLC now owns 297,903 shares of the company's stock valued at $16,751,000 after buying an additional 120,502 shares in the last quarter. Finally, Natixis Advisors LLC purchased a new position in shares of Catalent in the 3rd quarter valued at $1,287,000.

Insider Buying and Selling at Catalent

In other Catalent news, insider David Mcerlane sold 1,994 shares of the company's stock in a transaction dated Thursday, September 26th. The shares were sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares in the company, valued at approximately $2,177,150.88. This represents a 5.21 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Michelle R. Ryan sold 2,800 shares of the business's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $59.70, for a total transaction of $167,160.00. Following the completion of the transaction, the director now directly owns 10,835 shares of the company's stock, valued at approximately $646,849.50. This represents a 20.54 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 5,114 shares of company stock valued at $305,931 over the last quarter. Corporate insiders own 0.31% of the company's stock.

Analysts Set New Price Targets

Several research analysts have commented on the company. StockNews.com lowered Catalent from a "hold" rating to a "sell" rating in a research report on Friday, November 22nd. Baird R W cut shares of Catalent from a "strong-buy" rating to a "hold" rating in a report on Tuesday, September 24th. William Blair reissued a "market perform" rating on shares of Catalent in a research report on Tuesday, September 3rd. Finally, Robert W. Baird reaffirmed a "neutral" rating and issued a $63.50 target price on shares of Catalent in a report on Tuesday, September 24th. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Hold" and an average price target of $63.40.

Catalent Price Performance

Shares of NYSE CTLT traded up $0.12 during trading on Friday, hitting $61.12. 771,191 shares of the company were exchanged, compared to its average volume of 2,030,913. The company has a debt-to-equity ratio of 1.38, a current ratio of 2.51 and a quick ratio of 1.96. Catalent, Inc. has a 1 year low of $36.74 and a 1 year high of $61.50. The company has a market cap of $11.09 billion, a price-to-earnings ratio of -27.04, a PEG ratio of 2.42 and a beta of 1.16. The firm's fifty day moving average price is $59.87 and its 200 day moving average price is $58.43.

Catalent (NYSE:CTLT - Get Free Report) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative return on equity of 0.66% and a negative net margin of 9.28%. The firm had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.06 billion. During the same period last year, the firm earned ($0.10) EPS. Catalent's revenue was up 4.2% compared to the same quarter last year. On average, sell-side analysts expect that Catalent, Inc. will post 0.84 earnings per share for the current fiscal year.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.